WaveMan
WaveMan · Company
VCEL · Vericel Corp
> Search tickers & screens ⌘K
LIVE
← All companies

VCEL Vericel (VCEL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000887359
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
186
13F, latest reported quarter
Conversions, 180 days
13
Codes C/M, not in net · $1.4M priced

What the filings say about VCEL

Insiders, 180 days
-$4.4M net sold
7 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$988.6K
3 notices

Vericel insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Vericel Corp insiders sold a net $4.4M of stock across 143 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
MCLAUGHLIN KEVIN F
Director
SELL
2026-08-14 SECtraded 2026-08-12
7,000
$311.7K
-1.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on May 13, 2026.
  • The trade is 38.3% of the 18,300 shares held after it.
  • 2 other insiders sold within 30 days.
  • 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MCLAUGHLIN KEVIN F sold about $311.7K of VCEL on Aug 12, 2026; 2 other insiders sold within 30 days and 186 funds added in the latest 13F quarter.
Halpin Michael
Chief Operating Officer
SELL
2026-08-05 SECtraded 2026-08-03
10,000
$468.4K
-3.8%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 18, 2026.
  • The trade is 61.0% of the 16,394 shares held after it.
  • 2 other insiders sold within 30 days.
  • 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Halpin Michael sold about $468.4K of VCEL on Aug 3, 2026; 2 other insiders sold within 30 days and 186 funds added in the latest 13F quarter.
SIEGAL JONATHAN
Principal Accounting Officer
SELL
2026-07-31 SECtraded 2026-07-30
1,500
$73.3K
-6.5%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jun 26, 2026.
  • The trade is 139.1% of the 1,078 shares held after it.
  • 2 other insiders sold within 30 days.
  • 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer SIEGAL JONATHAN sold about $73.3K of VCEL on Jul 30, 2026; 2 other insiders sold within 30 days and 186 funds added in the latest 13F quarter.
SIEGAL JONATHAN
Principal Accounting Officer
SELL
2026-07-31 SECtraded 2026-07-30
2,500
$122.2K
-6.5%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jun 26, 2026.
  • The trade is 231.9% of the 1,078 shares held after it.
  • 2 other insiders sold within 30 days.
  • 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer SIEGAL JONATHAN sold about $122.2K of VCEL on Jul 30, 2026; 2 other insiders sold within 30 days and 186 funds added in the latest 13F quarter.
SIEGAL JONATHAN
Principal Accounting Officer
SELL
2026-07-31 SECtraded 2026-07-30
500
$24.4K
-6.5%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jun 26, 2026.
  • The trade is 46.4% of the 1,078 shares held after it.
  • 2 other insiders sold within 30 days.
  • 186 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer SIEGAL JONATHAN sold about $24.4K of VCEL on Jul 30, 2026; 2 other insiders sold within 30 days and 186 funds added in the latest 13F quarter.
143 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 138 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.4M over 180 days
-$1.0M over 90 days
below 78% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
186 funds bought in last quarter
more than 88% of Pharma & Biotech
Revenue
+16.5% year over year
more than 64% of Pharma & Biotech
Margin
6.0% net margin
more than 77% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.3% of the float short (float per yahoo 2026-10-26) · 9.6 days to cover · settled 2026-09-30
more than 72% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch VCEL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+18.1%12M
-19%-2%+15%+33%2025-102025-122026-022026-042026-062026-082026-10 2026-06-26 · Flynn Sean C. sold $684.6K2026-06-18 · Flynn Sean C. sold $603.1K2026-03-02 · Flynn Sean C. sold $530.4K2026-03-23 · Hagen Heidi sold $486.1K2026-08-03 · Halpin Michael sold $468.4K2026-01-07 · Halpin Michael sold $404.8K2026-06-18 · Halpin Michael sold $402.4K2026-03-02 · Halpin Michael sold $363.8K2026-08-12 · MCLAUGHLIN KEVIN F sold $311.7K2025-11-06 · Halpin Michael sold $297.8K2025-11-10 · MCLAUGHLIN KEVIN F sold $270.1K2026-05-11 · Wotton Paul K sold $244.8K2026-02-11 · MCLAUGHLIN KEVIN F sold $242.6K2026-06-26 · Hopper Jonathan Mark sold $225.0K2026-06-26 · Mara Joseph Anthony Jr sold $223.8K2026-03-02 · Flynn Sean C. sold $223.1K2026-05-07 · Mara Joseph Anthony Jr sold $202.5K2026-06-02 · Hopper Jonathan Mark sold $153.1K2026-05-06 · SIEGAL JONATHAN sold $130.5K2026-07-30 · SIEGAL JONATHAN sold $122.2K2026-04-02 · Hopper Jonathan Mark sold $121.5K2026-05-13 · MCLAUGHLIN KEVIN F sold $114.9K2026-05-13 · MCLAUGHLIN KEVIN F sold $114.9K2026-06-26 · SIEGAL JONATHAN sold $112.2K2025-11-11 · Halpin Michael sold $106.8K2025-12-02 · Wotton Paul K sold $94.9K2025-12-03 · Wotton Paul K sold $94.6K2026-05-11 · Wotton Paul K sold $82.6K2026-07-30 · SIEGAL JONATHAN sold $73.3K2025-12-02 · Hopper Jonathan Mark sold $64.7K2026-05-07 · SIEGAL JONATHAN sold $57.6K2026-07-30 · SIEGAL JONATHAN sold $24.4K2026-06-26 · SIEGAL JONATHAN sold $10.4K2026-08-12 · MCLAUGHLIN KEVIN F filed to sell $308.8K2026-08-03 · Halpin Michael filed to sell $459.8K2026-07-30 · SIEGAL JONATHAN filed to sell $220.1K2026-06-26 · Flynn Sean C. filed to sell $684.7K2026-06-26 · Hopper Jonathan Mark filed to sell $450.0K2026-06-26 · Mara Joseph Anthony Jr filed to sell $223.8K2026-06-26 · SIEGAL JONATHAN filed to sell $122.7K2026-06-18 · Flynn Sean C. filed to sell $603.1K2026-06-18 · Halpin Michael filed to sell $402.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VCEL: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
8,092,226 sh
$360.0M
STATE STREET CORP
3,293,975 sh
$146.6M
CONGRESS ASSET MANAGEMENT CO
2,916,295 sh
$129.7M
VANGUARD CAPITAL MANAGEMENT LLC
2,255,728 sh
$100.4M
Conestoga Capital Advisors, LLC
2,083,832 sh
$92.7M

Congress trades in VCEL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VCEL planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MCLAUGHLIN KEVIN F
Filed 2026-08-12
$308.8K
Halpin Michael
Filed 2026-08-03
$459.8K
SIEGAL JONATHAN
Filed 2026-07-30
$220.1K
Flynn Sean C.
Filed 2026-06-26
$684.7K
Hopper Jonathan Mark
Filed 2026-06-26
$450.0K

VCEL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Brown Capital Management Small Company Fund
$16.6M position · as of 2026-06-30
5.2%
Osterweis Opportunity Fund
$13.5M position · as of 2026-06-30
3.5%
Invesco Biotechnology & Genome ETF
$9.2M position · as of 2026-07-31
3.3%
CONESTOGA SMALL CAP FUND
$58.2M position · as of 2026-06-30
2.8%
Congress Small Cap Growth Fund
$50.1M position · as of 2026-07-31
2.5%
Nationwide Geneva Small Cap Growth Fund
$17.0M position · as of 2026-07-31
2.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 3
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$11.2M
$169.2K
$2.6M
+17%
+20%
2024
$10.2M
$18.8M
$2.7M
+78%
-9%
2023
$7.1M
$11.0M
$1.9M
+15%
-8%
2022
$8.7M
$905.2K
$2.4M
-15%
-11%
2021
$13.2M
$15.2M
$3.5M
+27%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.4M sold by insiders over 180 days, 186 funds added last quarter, $988.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

VCEL financials

Revenue growth
+16.5%
XBRL, annual
Net margin
6.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$306.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+7.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$61.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.04x
long-term debt only, 2018-09-30 (94 months older than the period end); equity 2026-06-30
Cash flow to debt
5.28x
TTM operating cash flow over long-term debt only, 2018-09-30 (94 months older than the period end)
Return on equity
+7.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+5.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+4.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
91.57x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$2.1B
market value at close 2026-10-26 on 2026-07-24 shares, plus long-term debt only, 2018-09-30 (94 months older than the period end), minus cash 2026-06-30
FCF yield
+2.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
0.35x
P/E over trailing EPS growth of 262%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$276.3M$237.2M$197.5M$164.4M
Gross profit$205.6M$172.1M$135.6M$109.8M
Operating income$11.0M$4.5M-$6.5M-$17.1M
Net income$16.5M$10.4M-$3.2M-$16.7M
EPS (diluted)0.320.20-0.07-0.35
Operating cash flow$51.9M$58.2M$35.3M$17.7M
Cash$100.1M$74.5M$69.1M$51.1M
SEC XBRL, fiscal years, as known on 2026-10-27

VCEL Stock Sonar score 6/7 axes

Find similar shapesCompare

VCEL ranks highest on institutional and government (88th percentile) and profitability (86th), and lowest on insider conviction (10th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
86
Inputs
  • Return on equity+7.2% · 83 pct, sector of 545
  • Return on assets+5.2% · 86 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+4.3% · 87 pct, sector of 576
Financial health
81
Inputs
  • Debt to equity0.04x · 66 pct, sector of 352
  • Cash flow to debt5.28x · 96 pct, sector of 371
Growth
64
Inputs
  • Revenue growth, YoY+16.5% · 64 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
10
Inputs
  • Net Form 4 buying (codes P and S), 180d-$4.4M · 20 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
88
Inputs
  • Funds adding, latest quarter186 · 88 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
41
Inputs
  • Short interest, % of float+10.3% · 38 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+12.0% · 43 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VCEL filings, in plain words

Are Vericel insiders buying or selling VCEL?

In the 180 days to 2026-10-27, Vericel insiders were net sellers, a net $4.4M across purchases and sales reported on Form 4, by 7 sellers.

Are there planned insider sales of VCEL?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $988.6K of stock; the latest, by MCLAUGHLIN KEVIN F, was filed 2026-08-12.

Read the full summary

In the 180 days to 2026-10-27, Vericel insiders were net sellers of VCEL, a net $4.4M across purchases and sales reported on Form 4 by 7 sellers. None of the 20 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $988.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies